keyword
MENU ▼
Read by QxMD icon Read
search

relapse malaria

keyword
https://www.readbyqxmd.com/read/27906962/population-density-climate-variables-and-poverty-synergistically-structure-spatial-risk-in-urban-malaria-in-india
#1
Mauricio Santos-Vega, Menno J Bouma, Vijay Kohli, Mercedes Pascual
BACKGROUND: The world is rapidly becoming urban with the global population living in cities projected to double by 2050. This increase in urbanization poses new challenges for the spread and control of communicable diseases such as malaria. In particular, urban environments create highly heterogeneous socio-economic and environmental conditions that can affect the transmission of vector-borne diseases dependent on human water storage and waste water management. Interestingly India, as opposed to Africa, harbors a mosquito vector, Anopheles stephensi, which thrives in the man-made environments of cities and acts as the vector for both Plasmodium vivax and Plasmodium falciparum, making the malaria problem a truly urban phenomenon...
December 2016: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/27905633/-failure-to-radical-cure-in-plasmodium-vivax-malaria
#2
Julián García, Agustín Seijo, Andrés Benchetrit, Esteban Couto, Sofía Echazarreta, Susana Lloveras, Tomás Orduna
Relapsing Plasmodium vivax malaria is due to activation of dormant intrahepatic parasitic forms known as hypnozoits. Primaquine is the only available drug effective against hypnozoits and, alongside a schizonticidal drug, constitutes the radical treatment of malaria. Failure of radical treatment is frequently attributed to inadequate dosing, poor adherence, or reinfection. However, several cases of radical treatment failure without these factors have been reported, inferring that metabolic properties of the host or tolerance mechanisms of the parasite may be implied...
August 2016: Revista Chilena de Infectología: órgano Oficial de la Sociedad Chilena de Infectología
https://www.readbyqxmd.com/read/27859692/louse-borne-relapsing-fever-in-finland-in-two-asylum-seekers-from-somalia
#3
Jukka Hytönen, Tamim Khawaja, Juha O Grönroos, Anna Jalava, Seppo Meri, Jarmo Oksi
We report two cases of louse-borne relapsing fever (LBRF) in young Somali asylum seekers having recently arrived to Finland. They had sought medical attention for a febrile illness. Blood smears were examined for suspected malaria, but instead, spirochete shaped bacteria were observed. The bacteria were confirmed as Borrelia recurrentis by PCR and sequencing. The patients survived, but their treatment was complicated by Jarisch-Herxheimer reaction. We conclude that LBRF must be considered as a diagnostic option in febrile refugees also in the northernmost parts of Europe...
November 16, 2016: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/27812090/diagnosis-of-persistent-fever-in-the-tropics-set-of-standard-operating-procedures-used-in-the-nidiag-febrile-syndrome-study
#4
Emilie Alirol, Ninon Seiko Horie, Barbara Barbé, Veerle Lejon, Kristien Verdonck, Philippe Gillet, Jan Jacobs, Philippe Büscher, Basudha Kanal, Narayan Raj Bhattarai, Sayda El Safi, Thong Phe, Kruy Lim, Long Leng, Pascal Lutumba, Deby Mukendi, Emmanuel Bottieau, Marleen Boelaert, Suman Rijal, François Chappuis
In resource-limited settings, the scarcity of skilled personnel and adequate laboratory facilities makes the differential diagnosis of fevers complex [1-5]. Febrile illnesses are diagnosed clinically in most rural centers, and both Rapid Diagnostic Tests (RDTs) and clinical algorithms can be valuable aids to health workers and facilitate therapeutic decisions [6,7]. The persistent fever syndrome targeted by NIDIAG is defined as presence of fever for at least one week. The NIDIAG clinical research consortium focused on potentially severe and treatable infections and therefore targeted the following conditions as differential diagnosis of persistent fever: visceral leishmaniasis (VL), human African trypanosomiasis (HAT), enteric (typhoid and paratyphoid) fever, brucellosis, melioidosis, leptospirosis, malaria, tuberculosis, amoebic liver abscess, relapsing fever, HIV/AIDS, rickettsiosis, and other infectious diseases (e...
November 2016: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/27809883/alternatives-to-currently-used-antimalarial-drugs-in-search-of-a-magic-bullet
#5
REVIEW
Akshaya Srikanth Bhagavathula, Asim Ahmed Elnour, Abdulla Shehab
Malaria is a major cause of morbidity and mortality in many African countries and parts of Asia and South America. Novel approaches to combating the disease have emerged in recent years and several drug candidates are now being tested clinically. However, it is long before these novel drugs can hit the market, especially due to a scarcity of safety and efficacy data.To reduce the malaria burden, the Medicines for Malaria Venture (MMV) was established in 1999 to develop novel medicines through industry and academic partners' collaboration...
November 4, 2016: Infectious Diseases of Poverty
https://www.readbyqxmd.com/read/27743866/why-do-some-primate-malarias-relapse
#6
Nicholas J White
Relapse may have evolved in malaria as a mechanism to avoid suppression by more virulent species in mixed infections, thereby increasing transmission opportunities. Later evolution of long latency in Plasmodium vivax was a necessary adaptation as early hominins moved to colder areas with shorter mosquito breeding seasons. Genetic diversity was maintained through heterologous hypnozoite activation.
October 12, 2016: Trends in Parasitology
https://www.readbyqxmd.com/read/27714452/malaria-relapses-were-already-known-before-1900-a-discussion
#7
Gabriele Franken, Marita Bruijns-Pötschke, Joachim Richter, Heinz Mehlhorn, Alfons Labisch
For a long time, only two phases of the life cycle of the agents of malaria parasites were known: the cycle inside the mosquito body and the cycle in the red blood cells of humans as intermediate hosts. A possible tissue development cycle inside humans, however, had already been proposed before 1900. In general, Pieter Klaesz Pel is considered the first scientist who has described such a tissue cycle. However, a closer look at Pel's work shows that he still followed an old (conservative) way of thinking, since he still referred to "malaria poison and malaria miasma...
October 7, 2016: Parasitology Research
https://www.readbyqxmd.com/read/27708190/plasmodium-vivax-landscape-in-brazil-scenario-and-challenges
#8
Andre M Siqueira, Oscar Mesones-Lapouble, Paola Marchesini, Vanderson de Souza Sampaio, Patricia Brasil, Pedro L Tauil, Cor Jesus Fontes, Fabio T M Costa, Claudio T Daniel-Ribeiro, Marcus V G Lacerda, Camila P Damasceno, Ana Carolina S Santelli
Brazil is the largest country in Latin America. Furthermore, a considerable portion of its territory is located within the Amazon region in the north. As a result, Brazil has reported half of the total malaria cases in the Americas in the last four decades. Recent progress in malaria control has been accompanied by an increasing proportion of Plasmodium vivax, underscoring a need for a better understanding of management and control of this species and associated challenges. Among these challenges, the contribution of vivax malaria relapses, earlier production of gametocytes (compared with Plasmodium falciparum), inexistent methods to diagnose hypnozoite carriers, and decreasing efficacy of available antimalarials need to be addressed...
October 5, 2016: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/27708189/epidemiology-and-control-of-plasmodium-vivax-in-afghanistan
#9
Toby Leslie, Sami Nahzat, Walid Sediqi
Around half of the population of Afghanistan resides in areas at risk of malaria transmission. Two species of malaria (Plasmodium vivax and Plasmodium falciparum) account for a high burden of disease-in 2011, there were more than 300,000 confirmed cases. Around 80-95% of malaria is P. vivax Transmission is seasonal and focal, below 2,000 m in altitude, and in irrigated areas which allow breeding of anopheline mosquito vectors. Malaria risk is stratified to improve targeting of interventions. Sixty-three of 400 districts account for ∼85% of cases, and are the target of more intense control efforts...
October 5, 2016: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/27708188/epidemiology-of-plasmodium-vivax-malaria-in-india
#10
Anupkumar R Anvikar, Naman Shah, Akshay C Dhariwal, Gagan Singh Sonal, Madan Mohan Pradhan, Susanta K Ghosh, Neena Valecha
Historically, malaria in India was predominantly caused by Plasmodium vivax, accounting for 53% of the estimated cases. After the spread of drug-resistant Plasmodium falciparum in the 1990s, the prevalence of the two species remained equivalent at the national level for a decade. By 2014, the proportion of P. vivax has decreased to 34% nationally, but with high regional variation. In 2014, P. vivax accounted for around 380,000 malaria cases in India; almost a sixth of all P. vivax cases reported globally. Plasmodium vivax has remained resistant to control measures, particularly in urban areas...
October 5, 2016: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/27708185/epidemiology-of-plasmodium-vivax-in-indonesia
#11
Claudia Surjadjaja, Asik Surya, J Kevin Baird
Endemic malaria occurs across much of the vast Indonesian archipelago. All five species of Plasmodium known to naturally infect humans occur here, along with 20 species of Anopheles mosquitoes confirmed as carriers of malaria. Two species of plasmodia cause the overwhelming majority and virtually equal shares of malaria infections in Indonesia: Plasmodium falciparum and Plasmodium vivax The challenge posed by P. vivax is especially steep in Indonesia because chloroquine-resistant strains predominate, along with Chesson-like strains that relapse quickly and multiple times at short intervals in almost all patients...
October 5, 2016: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/27706158/colorimetric-detection-of-plasmodium-vivax-in-urine-using-msp10-oligonucleotides-and-gold-nanoparticles
#12
Yossef Alnasser, Cusi Ferradas, Taryn Clark, Maritza Calderon, Alejandro Gurbillon, Dionicia Gamboa, Uri S McKakpo, Isabella A Quakyi, Kwabena M Bosompem, David J Sullivan, Joseph M Vinetz, Robert H Gilman
Plasmodium vivax is the most prevalent cause of human malaria in the world and can lead to severe disease with high potential for relapse. Its genetic and geographic diversities make it challenging to control. P. vivax is understudied and to achieve control of malaria in endemic areas, a rapid, accurate, and simple diagnostic tool is necessary. In this pilot study, we found that a colorimetric system using AuNPs and MSP10 DNA detection in urine can provide fast, easy, and inexpensive identification of P. vivax...
October 2016: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/27697758/pharmacokinetic-interactions-between-tafenoquine-and-dihydroartemisinin-piperaquine-or-artemether-lumefantrine-in-healthy-adult-subjects
#13
Justin A Green, Khadeeja Mohamed, Navin Goyal, Samia Bouhired, Azra Hussaini, Siôn W Jones, Gavin C K W Koh, Ivan Kostov, Maxine Taylor, Allen Wolstenholm, Stephan Duparc
Tafenoquine is in development as a single-dose treatment for relapse prevention in Plasmodium vivax malaria. Tafenoquine must be co-administered with a blood schizonticide; either chloroquine or artemisinin-based combination therapy (ACT). This open-label, randomized, parallel-group study evaluated potential drug interactions between tafenoquine and two ACTs: dihydroartemisinin-piperaquine or artemether-lumefantrine. Healthy volunteers of either sex, aged 18-65 years, without glucose-6-phosphate dehydrogenase deficiency, were randomized into five cohorts (n=24 per cohort) to receive tafenoquine on day 1 (300 mg) plus: once daily dihydroartemisinin-piperaquine on days 1, 2 and 3 (120:960 mg for 36-<75 kg bodyweight; 160:1280 mg for ≥75-100 kg bodyweight); or artemether-lumefantrine (80:480 mg) two doses 8 h apart on day 1, then twice daily on days 2 and 3; or each drug given alone...
October 3, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27663527/plasmodium-vivax-msp-3%C3%AE-polymorphisms-analysis-in-the-indian-subcontinent
#14
Anju Verma, Hema Joshi, Vineeta Singh, Anup Anvikar, Neena Valecha
BACKGROUND: Plasmodium vivax is the most widely distributed human malaria parasite and accounts for approximately the same number of malaria cases as Plasmodium falciparum in India. Compared with P. falciparum, P. vivax is difficult to eradicate because of its tendency to cause relapses, which impacts treatment and control strategies. The genetic diversity of these parasites, particularly of the merozoite surface protein-3 alpha (msp-3α) gene, can be used to help develop a potential vaccine...
2016: Malaria Journal
https://www.readbyqxmd.com/read/27598631/validation-of-the-rapid-test-carestart-tm-g6pd-among-malaria-vivax-infected-subjects-in-the-brazilian-amazon
#15
Marcelo Augusto Mota Brito, Henry Maia Peixoto, Anne Cristine Gomes de Almeida, Maria Regina Fernandes de Oliveira, Gustavo Adolfo Sierra Romero, José Pereira Moura-Neto, Nakul Singh, Wuelton Marcelo Monteiro, Marcus Vinícius Guimarães de Lacerda
INTRODUCTION: In the Brazilian Amazon, malaria infections are primarily caused by Plasmodium vivax. The only drug that kills the hypnozoite form of P. vivax is primaquine, thereby preventing relapse. However, treating glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals with primaquine can lead to severe hemolysis. G6PD deficiency (G6PDd) affects approximately 400 million people worldwide, most of whom live in malaria-endemic areas. Therefore, clinicians need tools that can easily and reliably identify individuals with G6PDd...
July 2016: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/27590312/plasmodium-cynomolgi-infections-in-rhesus-macaques-display-clinical-and-parasitological-features-pertinent-to-modelling-vivax-malaria-pathology-and-relapse-infections
#16
Chester Joyner, Alberto Moreno, Esmeralda V S Meyer, Monica Cabrera-Mora, Jessica C Kissinger, John W Barnwell, Mary R Galinski
BACKGROUND: Plasmodium vivax infections in humans or in new world monkeys pose research challenges that necessitate the use of alternative model systems. Plasmodium cynomolgi is a closely related species that shares genetic and biological characteristics with P. vivax, including relapses. Here, the haematological dynamics and clinical presentation of sporozoite-initiated P. cynomolgi infections in Macaca mulatta (rhesus macaques) are evaluated over a 100-day period. METHODS: Five M...
2016: Malaria Journal
https://www.readbyqxmd.com/read/27572973/a-global-map-of-genetic-diversity-in-babesia-microti-reveals-strong-population-structure-and-identifies-variants-associated-with-clinical-relapse
#17
Jacob E Lemieux, Alice D Tran, Lisa Freimark, Stephen F Schaffner, Heidi Goethert, Kristian G Andersen, Suzane Bazner, Amy Li, Graham McGrath, Lynne Sloan, Edouard Vannier, Dan Milner, Bobbi Pritt, Eric Rosenberg, Sam Telford, Jeffrey A Bailey, Pardis C Sabeti
Human babesiosis caused by Babesia microti is an emerging tick-borne zoonosis of increasing importance due to its rising incidence and expanding geographic range(1). Infection with this organism, an intraerythrocytic parasite of the phylum Apicomplexa, causes a febrile syndrome similar to malaria(2). Relapsing disease is common among immunocompromised and asplenic individuals(3,4) and drug resistance has recently been reported(5). To investigate the origin and genetic diversity of this parasite, we sequenced the complete genomes of 42 B...
2016: Nature Microbiology
https://www.readbyqxmd.com/read/27557982/non-falciparum-malaria-in-dakar-a-confirmed-case-of-plasmodium-ovale-wallikeri-infection
#18
Mamadou A Diallo, Aida S Badiane, Khadim Diongue, Awa Deme, Naomi W Lucchi, Marie Gaye, Tolla Ndiaye, Mouhamadou Ndiaye, Louise K Sene, Abdoulaye Diop, Amy Gaye, Yaye D Ndiaye, Diama Samb, Mamadou S Yade, Omar Ndir, Venkatachalam Udhayakumar, Daouda Ndiaye
BACKGROUND: Plasmodium ovale is rarely described in Senegal. A case of clinical malaria due to P. ovale wallikeri in West Central of Senegal is reported. CASE: A 34-year-old male baker in Dakar, with no significant previous medical history, was admitted to a health clinic with fever and vomiting. Fever had been lasting for 4 days with peaks every 48 h. As monospecific Plasmodium falciparum HRP-2 RDT was negative, he was treated with antibiotics. However, owing to persisting symptoms, he was referred to the emergency unit of the Youssou Mbargane Diop Hospital, Dakar, Senegal...
2016: Malaria Journal
https://www.readbyqxmd.com/read/27530139/management-of-relapsing-plasmodium-vivax-malaria
#19
Cindy S Chu, Nicholas J White
INTRODUCTION: Relapses are important contributors to illness and morbidity in Plasmodium vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria. A review was conducted with publications in English, French, Portuguese and Spanish using the search terms 'P. vivax' and 'relapse'. AREAS COVERED: Hypnozoites causing relapses may be activated weeks or months after initial infection...
October 2016: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/27528800/tafenoquine-and-its-potential-in-the-treatment-and-relapse-prevention-of-plasmodium-vivax-malaria-the-evidence-to-date
#20
REVIEW
Yehenew A Ebstie, Solomon M Abay, Wondmagegn T Tadesse, Dawit A Ejigu
Despite declining global malaria incidence, the disease continues to be a threat to people living in endemic regions. In 2015, an estimated 214 million new malaria cases and 438,000 deaths due to malaria were recorded. Plasmodium vivax is the second most common cause of malaria next to Plasmodium falciparum. Vivax malaria is prevalent especially in Southeast Asia and the Horn of Africa, with enormous challenges in controlling the disease. Some of the challenges faced by vivax malaria-endemic countries include limited access to effective drugs treating liver stages of the parasite (schizonts and hypnozoites), emergence/spread of drug resistance, and misperception of vivax malaria as nonlethal...
2016: Drug Design, Development and Therapy
keyword
keyword
65118
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"